The BladderPath study showed mpMRI reduced TTCT by 45 days for MIBC patients, enhancing treatment efficiency without harming non-MIBC patients. Conducted in 17 UK hospitals, the study involved 143 ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...
Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has approved ...
Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback